Quick Summary

Schizonepeta tenuifolia is a traditional herbal medicine used primarily in East Asia, with historical applications for inflammatory and respiratory conditions. Current evidence includes preclinical research and its integration in traditional Chinese medicine (TCM) formulations, but direct high-quality clinical trial evidence specific to Schizonepeta tenuifolia remains limited. Research is ongoing to better understand its potential roles.

What is it?

Schizonepeta, known botanically as Schizonepeta tenuifolia, is a herb commonly used in traditional East Asian medicine. It is typically included as part of herbal blends in TCM aimed at managing symptoms related to inflammation and respiratory ailments.

Traditional Uses

Historically, Schizonepeta has been used in East Asian herbal medicine to address inflammatory conditions and respiratory issues such as colds and fevers. It is often combined with other herbs in formulas designed to modulate immune function and alleviate symptoms of respiratory infections.

Active Compounds

Schizonepeta contains various bioactive compounds characteristic of medicinal herbs used in TCM. These compounds are believed to contribute to its effects, although specific isolated active ingredients and their mechanisms require further elucidation through rigorous scientific study.

Potential Benefits with Evidence Levels

  • Pediatric Common Cold: Moderate certainty human clinical evidence. A 2025 systematic review and meta-analysis of 66 randomized controlled trials (7,176 pediatric participants) found that herbal medicines containing Schizonepeta improved total effective rates and reduced symptom severity and duration compared with conventional medicine. Adverse events were fewer and mostly mild gastrointestinal symptoms.
  • Mild-to-Moderate COVID-19: Low to moderate certainty human clinical evidence in combination treatment. A 2026 meta-analysis of 9 RCTs (1,159 subjects) reported that traditional Chinese medicine combined with western medicine improved clinical cure rates, lung inflammation absorption, and reduced hospital stay in mild-to-moderate COVID-19 patients. However, the specific contribution of Schizonepeta was not isolated.
  • Diabetes Management: Preclinical and secondary clinical evidence. A comprehensive 2026 review highlighted the potential of TCM herbs, including Schizonepeta tenuifolia, in glycemic control and diabetic complications through multi-target actions, but specific clinical data on Schizonepeta alone for diabetes management are limited.

Side Effects

Herbal medicines including Schizonepeta tenuifolia have shown a lower incidence of adverse events compared with conventional medicines in several clinical studies, primarily mild gastrointestinal symptoms. No severe adverse events directly linked to Schizonepeta have been documented. Occasionally, traditional medicines including related herbs have been associated with cutaneous adverse drug reactions, though Schizonepeta itself has not been specifically implicated. Rare hepatotoxicity with TCM herbs has been reported and should be monitored with appropriate clinical assessment.

Drug Interactions

A retrospective study found that herbal formulas may not significantly alter warfarin international normalized ratio (INR) values, suggesting no strong interaction risk. However, specific interactions involving Schizonepeta tenuifolia are not well characterized. Caution is advised when combining with anticoagulants or other medications due to limited interaction data.

Who Should Avoid It

No specific contraindications for Schizonepeta tenuifolia have been reported. Given the limited detailed safety and interaction data, use during pregnancy, breastfeeding, or in individuals with certain medical conditions should be cautious and under professional supervision. Assessment on a case-by-case basis is recommended.

Evidence Limitations

High-quality, large-scale randomized controlled trials specifically studying Schizonepeta tenuifolia as a single agent are lacking. Most existing clinical evidence stems from studies on multi-herb formulations, limiting the ability to isolate Schizonepeta’s individual effects. Safety data focused solely on Schizonepeta are sparse. Further rigorous research is needed to clarify efficacy, safety profile, mechanisms of action, and potential drug interactions.

References

  • Kim SD, Lee SW, Woo SC, et al. Pediatric efficacy and safety in common cold treated with herbal medicine (PEACH): a systematic review and meta-analysis. Front Pharmacol. 2025. https://pubmed.ncbi.nlm.nih.gov/41614073/
  • Chen S, Li H, Jiang Z, et al. Effects of Traditional Chinese Medicine on Restoring the immune balance of mild-to-moderate Patients with new coronavirus. Indian J Pharmacol. 2026. https://pubmed.ncbi.nlm.nih.gov/41766236/
  • Fan Y, Gong S, Wang X. Traditional Chinese medicine in diabetes management: a comprehensive review of mechanisms and therapeutic potential. Front Endocrinol (Lausanne). 2026. https://pubmed.ncbi.nlm.nih.gov/41852470/
  • Lu HY, Cho SY, Park SU, et al. Do herbal formulas influence the international normalized ratio of patients taking warfarin? A retrospective study. ISRN Pharmacol. 2015. https://pubmed.ncbi.nlm.nih.gov/25861354/
  • Barvaliya MJ, Chetan AC, Chandan N, et al. Suspected cutaneous adverse drug reactions reported with traditional medicines: analysis of data for United Nations Asia region from WHO VigiBase. Front Pharmacol. 2023. https://pubmed.ncbi.nlm.nih.gov/37324461/
  • Teschke R, Larrey D, Melchart D, Danan G. Traditional Chinese Medicine (TCM) and Herbal Hepatotoxicity: RUCAM and the Role of Novel Diagnostic Biomarkers Such as MicroRNAs. Medicines (Basel). 2016. https://pubmed.ncbi.nlm.nih.gov/28930128/

Last Reviewed

June 2024

Disclaimer: This information is intended for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before using any herbal products, especially if you are pregnant, breastfeeding, have existing health conditions, or are taking other medications.